Bengaluru Startup Cuts Drug Discovery Time With AI

Creating new medicines traditionally takes years and costs billions, requiring huge teams of specialists just to manage the complexity. Now a Bengaluru startup is changing that equation.

LiteFold, co-founded by Anindyadeep Sannigrahi, uses artificial intelligence to accelerate computational biology workflows. The platform handles tasks that once needed AI specialists, infrastructure experts, software engineers, and legal professionals working together.

What started as an open-source project has evolved into a proprietary platform drawing interest from biotech startups worldwide. These companies are desperate to reduce the decade-long timelines and enormous costs of bringing new drugs to market.

The impact goes beyond efficiency. Faster, cheaper drug development means breakthrough treatments can reach patients sooner. For rare diseases affecting small populations, reducing costs could make previously "unprofitable" cures financially viable.

Sannigrahi isn't charging academic researchers who use the platform, recognizing that computational protein design is still emerging. By keeping the tools accessible to universities and research institutions, LiteFold is democratizing technology that was once available only to pharmaceutical giants.

The Ripple Effect

When drug discovery becomes more accessible, smaller biotech firms can compete with industry giants. This increased competition could lead to more diverse research priorities, including treatments for neglected diseases that affect developing nations.

The platform also frees up human researchers to focus on creative problem-solving rather than administrative coordination. Scientists can spend more time on actual discovery instead of managing multidisciplinary teams.

As computational biology matures, tools like LiteFold could accelerate everything from cancer treatments to vaccines for emerging diseases.